2025 年 11 月 13 日 透過協議安排進行私有化 註： J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 交易是為本身帳戶進行的。 J.P. Morgan Securities PLC 是最終由 JPMorgan Chase & Co.擁有的公司。 | 交易方 | 日期 | 有關證券的 | 產品說明 | 交易性質 | 與衍生工具 | 到期日或清結日 | 參考價 | 已支付／已收取的 | 交易後數額（包括 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 說明 | | | 有關的參照 | | | 總金額 | 與其訂有協議或 | | | | | | | 證券數目 | | | | 達成諒解的任何 | | | | | | | | | | | 人士的證券） | | J.P. Morgan | 2025 年 11 月 12 日 | 衍生工具 | 其他類別產品 | 清結衍生工具合約 | 92,500 | 2026 年 12 月 2 日 | $9.1773 | $848,897.570 ...

就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說明 | | 交易性質 | 買入／賣出 | 涉及的股 | 已支付／已收取的 | 已支付或已收 | 已支付或已收 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 份總數 | 總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | | | （H） | （L） | | | J.P. Morgan | 2025 | 年 11 | 月 | 其他類別的證券 | | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 賣出 | 2,095,000 | $19,226,382.7500 | $9.1800 | | $9.1800 | | Securities | 12 日 | | | (例如: | 股權互換) | 產生的 Delta 1 產品的對沖活動 | | | | | | | | ...

註： J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 交易是為本身帳戶進行的。 交易披露 2025 年 11 月 12 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | 有關證券的說明 | 產品說明 | 交易性質 | 與衍生工具 | 到期日或清結日 | 參考價 | 已支付／已收 | 交易後數額（包括 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 有關的參照 | | | 取的總金額 | 與其訂有協議或 | | | | | | | 證券數目 | | | | 達成諒解的任何 | | | | | | | | | | | 人士的證券） | | J.P. Morgan | 2025年11月 | 衍生工具 | 其他類別產品 | 清結衍生工具合約 | 3,500 | 2025 年 12 月 29 日 | $9.1799 | $32,129.6500 | ...

J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 交易是為本身帳戶進行的。 J.P. Morgan Securities PLC 是最終由 JPMorgan Chase & Co.擁有的公司。 交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說明 | 交易性質 | | 買入／賣出 | 涉及的股份總 | 已支付／已收 | 已支付或已收 | 已支付或已收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 數 | 取的總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | | （H） | （L） | | J.P. Morgan | 2025 | 年 11 月 | 11 日 | 其他類別的證券 | 因全屬客戶主動發出且由客戶需求帶動的買 | | 賣出 | 1,000 | $9,188.3000 | $9.2000 | $9. ...

Group 1 - The Shenzhen Stock Exchange announced an adjustment to the constituents of the Hang Seng Composite Small Cap Index, affecting the list of eligible securities for the Hong Kong Stock Connect program [2] - Kangji Medical (09997) will be removed from the Hong Kong Stock Connect eligible securities list, effective from November 12, 2025 [2] - This adjustment is in accordance with the relevant provisions of the Shenzhen Stock Exchange's implementation rules for the Hong Kong Stock Connect program [2]

Core Insights - The article discusses the recent financial performance and strategic developments of the company, highlighting key metrics and future outlooks [2] Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching a total of 1.5 billion [2] - Net profit margin improved to 12%, up from 10% in the previous year, indicating enhanced operational efficiency [2] Strategic Developments - The company announced plans to expand its market presence in Asia, targeting a 20% growth in that region over the next two years [2] - A new product line is set to launch in Q3, expected to contribute an additional 200 million in revenue [2] Market Outlook - Analysts predict a continued upward trend in the industry, with an overall market growth rate of 8% annually [2] - The company is well-positioned to capitalize on emerging trends, particularly in digital transformation and sustainability initiatives [2]

Group 1 - The core point of the article is the adjustment of the Hang Seng Composite Small Cap Index, which will result in the removal of Kangji Medical (09997) from the Hong Kong Stock Connect eligible securities list effective November 12, 2025 [1]

Core Insights - The article discusses the recent financial performance and strategic developments of the company, highlighting key metrics and future outlooks [2] Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching a total of 1.5 billion [2] - Net profit margin improved to 12%, up from 10% in the previous year, indicating enhanced operational efficiency [2] Strategic Developments - The company has announced plans to expand its market presence in Asia, targeting a 20% growth in that region over the next two years [2] - A new product line is set to launch in Q3, expected to contribute an additional 200 million in revenue [2] Market Outlook - Analysts predict a continued upward trend in the industry, with an estimated growth rate of 8% annually over the next five years [2] - The company is well-positioned to capitalize on emerging market opportunities, particularly in technology and sustainability sectors [2]

Group 1 - The Hong Kong Stock Connect has adjusted its list of eligible securities, removing Kangji Medical (09997) from the list, effective from November 12 [1]

2025 年 11 月 11 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說明 | 交易性質 | | 買入／賣出 | 涉及的股份 | 已支付／已收取的 | 已支付或已收 | 已支付或已收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 總數 | 總金額 | 取的最高價（H） | 取的最低價（L） | | J.P. Morgan | 2025 | 年 11 | 月 | 其他類別的證券 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | | 賣出 | 4,000 | $36,416.2500 | $9.1600 | $9.0700 | | Securities | 10 日 | | | (例如: 股權互換) | 盤所產生的 Delta 1 | 產品的對沖活動 | | | | | | | PLC | | | | 其他類別的證券 | ...